# Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients

> **NCT03344822** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Central Hospital, Nancy, France** · enrollment: 33 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DIAGNOSTIC_TEST:** 68Ga-PSMA-11
- **DIAGNOSTIC_TEST:** 18F-Choline PET-CT

## Key facts

- **NCT ID:** NCT03344822
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-02
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344822, "Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03344822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*